Portal hypertension after prolonged use of trastuzumab emtansine: nodular regenerative hyperplasia with autoimmune features
DOI:
https://doi.org/10.33448/rsd-v10i8.17005Keywords:
Breast Neoplasms; Trastuzumab; Hypertension, Portal; Hepatitis, autoimmune.Abstract
We report a rare complication associated with prolonged use of trastuzumab emtansine (T-DM1) – a composed therapy for HER2+ breast cancer – presenting with laboratorial autoimmune features that could have delayed the diagnosis or led to misdiagnosis. A 55-year-old female was referred to the hepatologist with a computed tomography suggestive of portal hypertension for etiological investigation. History of invasive ductal carcinoma in the right breast undergoing treatment for 5 years. She had already undergone neoadjuvant chemotherapy, mastectomy, radiotherapy and adjuvant chemotherapy. By the time of metastatic diagnosis, she was in monotherapy with T-DM1 for 2.5 years. Upper endoscopy showed esophageal varices and portal hypertension gastropathy. Laboratorial tests revealed increased transaminases, hypergammaglobulinemia and positive antinuclear antibody. Liver biopsy was performed for autoimmune hepatitis differential diagnosis but revealed nodular regenerative hyperplasia. T-DM1 was discontinued. After a 2-year follow-up, the patient did not present any complications of portal hypertension, although persisted with esophageal varices.
References
Benguerfi, S., Diéras, V., Campone, M., Mosnier, J.-F., & Robert, M. (2020). Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages. Acta Oncologica, 59(3), 306–309. https://doi.org/10.1080/0284186X.2019.1670860
Diéras, V., Harbeck, N., Budd, G. T., Greenson, J. K., Guardino, A. E., Samant, M., & Krop, I. E. (2014). Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2013.54.4999
Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., & Gianni, L. (2017). Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology, 18(6), 732–742. https://doi.org/10.1016/S1470-2045(17)30312-1
Force, J., Saxena, R., Schneider, B. P., Storniolo, A. M., Sledge, G. W., Chalasani, N., & Vuppalanchi, R. (2016). Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. Journal of Clinical Oncology, 34(3), e9–e12. https://doi.org/10.1200/JCO.2013.49.8543
Hartleb, M. (2011). Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension. World Journal of Gastroenterology, 17(11), 1400. https://doi.org/10.3748/wjg.v17.i11.1400
Lepelley, M., Allouchery, M., Long, J., Boucherle, D., Ranchoup, Y., Marc’Hadour, F. Le, & Sturm, N. (2018). Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine? Annals of Hepatology, 17(6), 1067–1071. https://doi.org/10.5604/01.3001.0012.7207
Milam, P., Berger, M., Ramaswamy, B., Reinbolt, R., Wesolowski, R., & Kaffenberger, B. H. (2019). Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine. The Journal of Clinical and Aesthetic Dermatology, 12(7), 23–26. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/31531159
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009). Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast Journal. https://doi.org/10.1111/j.1524-4741.2009.00822.x
Remillard, S., Rebhun, L., Howie, G., & Kupchan, S. (1975). Antimitotic activity of the potent tumor inhibitor maytansine. Science, 189(4207), 1002–1005. https://doi.org/10.1126/science.1241159
Reshamwala, P. A., Kleiner, D. E., & Heller, T. (2006). Nodular regenerative hyperplasia: Not all nodules are created equal. Hepatology, 44(1), 7–14. https://doi.org/10.1002/hep.21258
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., & Wolmark, N. (2005). Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 353(16), 1673–1684. https://doi.org/10.1056/NEJMoa052122
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7–34. https://doi.org/10.3322/caac.21551
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., & Blackwell, K. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 367(19), 1783–1791. https://doi.org/10.1056/NEJMoa1209124
Blanco I., Labitigan M., & Abramowitz M. (2017). The Association between Anti-Nuclear Antibodies and Obesity is Likely Mediated by Abdominal Adiposity and Systemic Inflammation. Journal of Clinical & Cellular Immunology. 08(04). https://doi.org/10.4172/2155-9899.1000513
Colina, F., Pinedo, F., Solis, J., Moreno, D., & Nevado, M. (1992). Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology. 102(4):1319-1324. https://doi.org/10.1016/0016-5085(92)90771-P
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Gustavo Vargas Borgongino Monteiro; Marcela Chagas Lima Mussi; Mateus Jorge Nardelli; Bruno Campos Santos; Cláudia Alves Couto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
